Cytomegalovirus (HHV-5) Infections – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections – Drugs In Development, 2023’, provides an overview of the Cytomegalovirus (HHV-5) Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections
- The report reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cytomegalovirus (HHV-5) Infections therapeutics and enlists all their major and minor projects
- The report assesses Cytomegalovirus (HHV-5) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AlloVir IncBaylor College of Medicine
Biotest AG
Bristar Immunotech Biotechnology Co Ltd
Case Western Reserve University
Chengdu Rongsheng Pharmaceutical Co Ltd
Children's Hospital Los Angeles
Children's National Hospital
Children's National Research Institute
Children's Research Institute
China Biologic Products Holdings Inc
China Immunotech Co Ltd
China Medical System Holdings Ltd
Citranvi Biosciences LLC
City of Hope
Cyrus Biotechnology Inc
Danuvius BioSciences
Emory University
Evaxion Biotech A/S
Evrys Bio
George Papanicolaou Hospital
Ghent University Hospital
GSK plc
Hannover Medical School
Harvard University
Heidelberg University Hospital
Helleday Laboratory
Helocyte Biosciences Inc
Hookipa Pharma Inc
Hospital Israelita Albert Einstein
Huinuo Biomedical Technology Co Ltd
Icahn School of Medicine at Mount Sinai
iCELL Biotechnology Co Ltd
Immunetune BV
Instituto de investigacion sanitaria Marques de Valdecilla
Istituto Giannina Gaslini
Johns Hopkins University
Leiden University Medical Center
Lion TCR Pte Ltd
Ludwig-Maximilians-University Munich
Manuka Inc
Medical College of Wisconsin
Memo Therapeutics AG
Merck & Co Inc
Microbiotix Inc
Moderna Inc
Nobelpharma Co Ltd
Okogen Inc
Peking University
Peking University People's Hospital
Phoenix Biotechnology Inc
QIMR Berghofer Medical Research Institute
Roswell Park Cancer Institute
RQ Biotechnology Ltd
Sanford Burnham Prebys Medical Discovery Institute
Savoy Pharmaceuticals Inc
Shanxi Kangbao Biological Product Co Ltd
Shenzhen Geno-Immune Medical Institute
Sisu Pharma Inc
SL VaxiGen Inc
SpyBiotech Ltd
Stadius Biopharma LLC
SymBio Pharmaceuticals Ltd
Synklino ApS
Takeda Pharmaceutical Co Ltd
Trellis Bioscience LLC
University of Pittsburgh
University of Science and Technology of China
University of Tennessee Research Foundation
University of Texas MD Anderson Cancer Center
University of Wisconsin Madison
Vall d'Hebron Institute of Oncology (VHIO)
VBI Vaccines Inc
Vichem Chemie Research Ltd
Viramatix Sdn Bhd
ViroKyne Therapeutics LLC
VxBiosciences Inc
Western Sydney Local Health District (Australia)
Westmead Hospital
Yale University
Zevra Therapeutics Inc
Zhuhai Trinomab Biotechnology Co Ltd